Low-dose interleukin-2 therapy in autoimmune and inflammatory diseases: facts and hopes

Sci Bull (Beijing). 2023 Jan 15;68(1):10-13. doi: 10.1016/j.scib.2022.12.024. Epub 2022 Dec 27.

Authors

Zhan-Guo Li¹, Jing He², Miao Miao²

Affiliations

¹ Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis, Peking University People's Hospital, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China. Electronic address: li99@bjmu.edu.cn.
² Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis, Peking University People's Hospital, Beijing 100044, China.

PMID: 36621432
DOI: 10.1016/j.scib.2022.12.024

No abstract available

MeSH terms

Autoimmune Diseases* / drug therapy
Hope
Humans
Immunotherapy
Interleukin-2* / therapeutic use
Interleukin-6 / therapeutic use

Substances

Interleukin-2
Interleukin-6